Low gonorrhoea antimicrobial resistance and culture positivity rates in general practice: a pilot study

Maartje Visser 1, Mireille van Westreenen,2,3 Jan van Bergen,1,4,5 Birgit H B van Bentham1

ABSTRACT
Objective In the Netherlands, the Gonococcal Resistance to Antimicrobials Surveillance (GRAS) programme is carried out at Centres for Sexual Health (CSH), which provide care for sexual high-risk populations. However, half of gonorrhoea infections are diagnosed in general practice (GP). We performed a pilot study to explore expanding GRAS to GPs using laboratory-based surveillance. Additionally, antimicrobial resistance patterns of GP and CSH patients were compared.

Methods Three laboratories from different regions were included, which all perform gonorrhoea diagnostics for GPs and used ESWab for patient sampling. Additional culturing for all GP patients with gonorrhoea took place from February to July 2018. After positive PCR-nucleic acid amplification test, residual ESWab material was used for culture. In positive cultures, susceptibility testing was performed for azithromycin, ciprofloxacin, cefotaxime and ceftriaxone using Etest.

Results During the study period, 484 samples were put in culture. 16.5% of cultures were positive (n=80). Antimicrobial resistance levels were low, with 2.6% resistance to azithromycin, 21.5% to ciprofloxacin and 0.0% to cefotaxime and ceftriaxone. Resistance levels in CSH GRAS data (first half of 2018) were 19.2% for azithromycin, 31.5% for ciprofloxacin, 1.9% for cefotaxime and 0.0% for ceftriaxone.

Conclusions Culture positivity rates for GP patients were low, probably due to long transportation times and awaiting PCR test results before attempting culture. Positivity rates might be improved by making changes in sampling and/or transportation methods, but that would require involvement of GPs and patients instead of keeping the surveillance lab based. Resistance levels appeared to be lower at GPs than at the CSH, indicating that resistance might emerge first in more high-risk populations. It is important to consider all potentially relevant patient populations when establishing a gonococcal antimicrobial resistance surveillance programme. However, based on the findings from this study the current GRAS programme will not be extended to GPs.

INTRODUCTION
Neisseria gonorrhoeae infection (gonorrhoea) is one of the most common STIs in the Netherlands. In the past, N. gonorrhoeae has shown to be extremely capable of developing antimicrobial resistance, threatening the availability of effective treatment.1 Resistance to the current first-line antibiotic ceftriaxone has not yet been reported in the Netherlands,2 but has been seen in other countries, including the UK.3

To monitor gonorrhoea antimicrobial resistance in the Netherlands, the Gonococcal Resistance to Antimicrobials Surveillance (GRAS) programme was established in 2006. GRAS is a sentinel surveillance system including 18 out of 24 Centres for Sexual Health (CSH). However, more than half of gonorrhoea diagnoses in the Netherlands are carried out in general practice (GP). Thus, many patients are not included in GRAS. Currently, it is unknown to what extent antimicrobial resistance patterns among CSH visitors are representative for patients who visit the GP for STI testing. Gaining insight in the gonococcal antimicrobial resistance among GP patients could therefore provide useful information and will allow for a more comprehensive understanding of the current antimicrobial resistance patterns of gonorrhoea in the Netherlands.

In GP gonorrhoea diagnoses are based on PCR-nucleic acid amplification test (NAAT). STI testing guidelines for GPs are similar to those at the CSH, but it is known that, for example, extragenital testing is less often performed by GPs.4 Culture is also not routinely performed, but is necessary to determine antimicrobial susceptibility. Because it requires more effort from GPs and their patients to collect additional samples for culturing, we first wanted to explore implementation of a laboratory-based surveillance that requires no additional sample collection. Therefore, the primary goal of this pilot study was to explore the feasibility of a laboratory-based GP surveillance of gonococcal antimicrobial resistance. Additionally, we aim to describe antimicrobial resistance patterns of patients with gonorrhoea in GP, and compare these to patterns of CSH patients.

METHODS
Laboratories were eligible for inclusion in the pilot study if they performed gonorrhoea diagnostics for GPs, if they were equipped to perform culture and susceptibility testing for N. gonorrhoeae and if they used ESWab for collection and transportation of samples. ESWab is a collection and transport system that contains enough liquid sample suspension to perform multiple tests on one specimen. It is therefore possible to first perform PCR-NAAT diagnostics, and if positive for gonorrhoea perform culture...
using the same material. Three large laboratories participated in this study: one from an urban region (STAR-SHL) in the south-west of the Netherlands, and two from rural regions in the north of the Netherlands (Certe and Izore).

The three laboratories collected data from GP patients that tested positive for gonorrhoea from February to July 2018. After positive NAAT, ESwab material was used for culture. In case of a positive culture, antimicrobial susceptibility testing was performed using Etest for four antibiotics: azithromycin, ceftriaxone, ciprofloxacin and cefotaxime. The laboratories Certe and Izore did not culture urine samples and samples with a cycle threshold value over 30 due to low chance of succeeding. All labs reported data from both culture positive and negative patients, including sex, age, anatomical location of sampling, result of the regular GRAS surveillance at CSH from the first half of 2018.

**Results**

A total of 469 GP patients tested positive for gonorrhoea at the three laboratories between February and July 2018: 323 at STAR-SHL, 77 at Certe and 69 at Izore. Some patients had samples from multiple anatomical locations. Therefore, culture was performed on 484 samples, of which 80 (16.5%) were positive. All analyses were performed on sample level. Most samples were urogenital (n=395), followed by anal (n=42) and oral (n=29). Eighteen samples were of unknown anatomical location. Of the three laboratories, Izore had a significantly lower culture positivity rate (8.2% positive; OR 0.40, 95% CI 0.17 to 0.98) compared with STAR-SHL (18.1%) and Certe (17.5%). The anatomical location of the sample was also significantly associated with culture positivity. Compared with vaginal swabs (16.2% culture positive), anal swabs were less likely to result in a positive culture (2.4% positive; OR 0.13, 95% CI 0.02 to 0.95), as were oral swabs (0.0% positive). Cultures from urine samples showed a significantly higher chance of succeeding (25.7% positive; OR 1.80, 95% CI 1.02 to 3.18). Age and sex were not significantly associated with culture positivity in univariate analyses. See also online supplementary table 1. The 16.5% culture positivity rate at the GPs was lower than the average 54.7% culture positivity rate at the CSH in the first half of 2018.

Antimicrobial susceptibility testing was performed for the 80 positive cultures. Resistance levels were low, with 2.6% resistant to azithromycin, 21.5% to ciprofloxacin and 0.0% to cefotaxime and ceftriaxone. Resistance levels in CSH GRAS data (first half of 2018) were 19.2% for azithromycin, 31.5% for ciprofloxacin, 1.9% for cefotaxime and 0.0% for ceftriaxone. This difference was statistically significant for azithromycin (p<0.001), but not for ciprofloxacin (p=0.078) and cefotaxime (p=0.392). The MIC distributions including 95% CI from the GP population and the CSH population are shown in figure 1.

**Discussion**

This study piloted a laboratory-based antimicrobial resistance surveillance for GP patients, without GPs or patients being involved. Culture positivity rates were low, and antimicrobial resistance patterns from GP patients with data from the regular GRAS surveillance at CSH from the first half of 2018 using Fisher’s exact test.
resistance rates were lower than the rates seen in the GRAS programme at CSH.

The main limitation of this study was the small sample size. As this was a pilot study, we only enrolled the surveillance in three regions. We did however include both urban and rural laboratories, so the findings are expected to be representative for other regions in the Netherlands as well. Due to the low culture positivity rates, the amount of samples available for susceptibility testing was limited. Therefore, extensive statistical analyses could not be performed. Furthermore, due to the low culture positivity rate, the representativeness of the results of the susceptibility testing should be interpreted with caution.

The low GP culture positivity rate could be explained by the fact that in the pilot study PCR testing results had to be available before samples were put in culture, and as bacterial viability in a transport medium decreases over time,\(^a\) this delay might have caused decreases in culture positivity rates. According to the CSH GRAS protocol, PCR test results do not have to be awaited, and samples are put immediately in culture when received at the laboratory. In addition, transportation times from GP to laboratory could have been longer than at the CSH because GP practices are often further away from the laboratory, and because GPs did not know the samples would be used for culturing and therefore put in no additional efforts to ensure the samples were sent to the laboratory as soon as possible. The time between sample collection at GP and culturing was unknown at the laboratories. Samples were in all three laboratories collected from the GPs once per day. Estimations of time between sample collection and sample testing varied from a few hours to more than a day.

Results from this study also showed that the anatomical location of the sample was strongly associated with culture positivity. Anal and oral samples had a lower chance of resulting in positive culture, which has been seen before.\(^b,c,d\) The finding that urine samples had a higher chance of succeeding was unexpected, since two laboratories said not to culture urine samples due to low expected culture positivity. Despite the fact that this finding is only based on univariate analysis, it does indicate that urine could also be used for culturing.

Antimicrobial resistance rates were compared between the GP and CSH populations. For all antimicrobials, resistance levels were lower among GP patients. These findings were only statistically significant for azithromycin, which could be due to the small sample size, but it gives an indication that antimicrobial resistance might occur more often among CSH visitors. This could be explained by the fact that ‘core groups’ with high risk of STI are known contributors to dissemination of antimicrobial resistant gonorrhoea,\(^3\) and CSH provide care especially for groups at high risk for STI, while the GP population is generally at lower risk.

The main aim of this study was to explore the feasibility of a laboratory-based GP surveillance of gonococcal antimicrobial resistance. It was possible to perform surveillance without engaging GPs and/or their patients, but it resulted in low culture positivity rates. For a more comprehensive and complete surveillance system tests could not be performed. Furthermore, due to the low culture positivity rate, the representativeness of the results of the susceptibility testing should be interpreted with caution.

In conclusion, it is important to consider all potentially relevant patient populations when establishing a gonococcal antimicrobial resistance surveillance programme. However, the current findings indicate that additional efforts are needed to establish antimicrobial surveillance in GP practice, while resistance rates are low. Based on the findings from this study the current GRAS programme in the Netherlands will therefore not be extended to the GP population.

**Epidemiology**

**Handling editor** Claudia E Stcoutre

**Acknowledgements** The authors thank the Laboratories STAR-SHL, Izore and Cerfe and their staff for the collaboration and participation in the pilot study, and the GRAS board for their contributions to the study design and interpretation of the results.

**Contributors** All authors were involved in establishing the study design, MV coordinated the execution of the study, analysed the data and drafted the manuscript. All authors contributed to interpretation of the results and commented on the manuscript. All authors read and approved the final manuscript.

**Funding** This study was funded by the Dutch Ministry of Health, Welfare and Sport.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Ethics approval** This study used anonymised data collection without the involvement of the patient. This study was declared to fall outside the scope of the Dutch law on medical scientific research with human subjects (WMO) by the Medical Ethical committee of the Erasmus Medical Centre in Rotterdam (MEC-2017-570). Therefore, further ethical approval was not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data from this study are not publicly available, but may be provided for scientific purposes upon reasonable request.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.